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Impact of Transoral Endoscopic Vestibular Approach
Thyroidectomy on Pathologic Assessment
Stephen M. Smith, MD; Muhammad Ahmed, MD; Tobias Carling, MD, PhD; Robert Udelsman, MD, MBA;
Adebowale J. Adeniran, MD; Syed Gilani, MD; Manju L. Prasad, MD; Andrea L. Barbieri, MD

 Context.—Since 2016, transoral endoscopic thyroid
resection with vestibular approach (TOETVA) has become
increasingly performed in the United States. Although
guidelines for the procedure are evolving, indeterminate
and malignant preoperative cytopathologic diagnoses are
not a contraindication. There are limited data related to
the pathologic examination of these specimens.
Objective.—To examine the clinicopathologic features
of TOETVA specimens with particular attention to limitations of interpretation of pathologic parameters and final
diagnosis.
Design.—We reviewed age, sex, preoperative imaging
and cytologic diagnoses, surgical pathology, and clinical
follow-up data in TOETVA resections at our institution
between March 2016 and December 2019.
Results.—Fifty cases of TOETVA were identified, comprising 48 women and 2 men with a mean age of 47 years.
Preoperative cytologic diagnoses were available in 47
cases and included 19 nondiagnostic/benign (Bethesda I/
II), 24 follicular lesion of undetermined significance/

suspicious for follicular neoplasm (Bethesda III/IV), and 4
suspicious/malignant diagnoses (Bethesda V/VI). Thirtyfour cases (68%) among the surgical resection specimens
showed disruption and/or fragmentation. Thirty-nine cases
were negative for carcinoma, including hyperplasias and
benign/indolent neoplasms. Eleven cases exhibited papillary thyroid carcinoma. Final diagnoses were reached in all
disrupted/fragmented cases. In 2 cases of papillary thyroid
carcinoma, tumor size, microscopic extrathyroidal extension, and margin status could not be determined.
Conclusions.—A significant proportion of TOETVA
specimens are disrupted/fragmented, which can compromise information about tumors, including size, number,
margin status, and microscopic extrathyroidal extension.
Given that these parameters inform treatment and followup, this should be considered when selecting patients for
TOETVA.
(Arch Pathol Lab Med. doi: 10.5858/arpa.2021-0082OA)

T

procedure appeals to patients given that it eliminates the
need for a skin incision that may have undesirable cosmetic
results. The procedure is particularly popular in Asia.2–7
Disruption of the resected specimen(s) is documented in the
literature8,9 and occurs primarily either during the endoscopic dissection itself or during specimen extraction
through the small transoral tract.
We reported our experience using TOETVA performed
outside of Asia in 2016 in a limited series of 7 cases that
included 5 thyroids.10 Unlike the traditional transverse
cervical thyroidectomy specimens that are typically excised
intact, TOETVA-derived specimens are often received
fragmented and unoriented, and there are limited data
published on how this difference in specimen integrity
impacts the pathologic examination and resulting final
diagnostic information in tumors. For example, only 1 of the
5 thyroids in our initial report had papillary thyroid
carcinoma (PTC): 2 microcarcinomas, 7 mm and 2 mm,
with micrometastasis to central compartment lymph
nodes.10 Since the initial 5 cases, our experience in
pathology has grown to include 50 thyroids removed using
TOETVA, which we studied to determine how the
procedure affects pathologic examination and whether there
is any impact on diagnosis, including tumor parameters,
that may influence subsequent management, prognosis, and
treatment.

ransoral endoscopic thyroid resection with vestibular
approach (TOETVA) has become increasingly available
in the surgical management of both neoplastic and
nonneoplastic thyroid conditions in the past decade.1
Briefly, the endoscopic procedure accesses the neck via
intraoral incisions and subsequent dissection to reach the
thyroid gland. The thyroid can then be mobilized, dissected
endoscopically, and captured within a retrieval bag and
removed through the original intraoral incision. The
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MATERIALS AND METHODS
Selection of Cases
Institutional review board approval was obtained for this analysis
that included prospective pathologic examination of cases followed
by a retrospective review of clinical data. The department of
pathology laboratory information system and the hospital electronic medical record system were queried for transoral thyroidectomy specimens received since the start of this technique in
March 2016 through December 2019. Clinical information,
including age, sex, and follow-up data, where available, was
retrieved from the electronic medical record.
At our institution, 2 experienced endocrine surgeons performed
TOETVA following a period of specialized training in early 2016.
Patients were selected for the TOETVA procedure at the surgeons’
discretion based on preoperative assessment. Factors such as
morbid obesity, large substernal goiters, prior neck operation,
sonographic findings suggestive of extrathyroidal extension (ETE),
and/or lateral neck disease represented relative or absolute
contraindications. Lesion size was incorporated as part of this
assessment, but hard cutoff sizes were not used. The added
complexity of specimen retrieval was discussed with patients and
detailed discussions about the effect on pathologic analysis were
limited.

Pathologic Review
After the specimens were removed, gross and microscopic
examinations were performed prospectively on all cases as part of
ongoing patient care. All specimens were photographed upon
receipt in pathology, and specimen integrity was assessed as intact
when the specimen was received as a single piece with a smooth
surface without evidence of disruption of the thyroid pseudocapsule and disrupted when the specimen was received in multiple
fragments or with evidence of disrupted pseudocapsule revealing
the underlying parenchyma. Fragments (the number of separate
pieces) in disrupted cases were enumerated except when the
specimens were clearly morcellated into more than 20 pieces, in
which case ‘‘.20 fragments’’ was recorded. In cases where
malignancy was identified, microscopic assessment of the following
tumor parameters was recorded: tumor size, margin status, and
presence of microscopic ETE. The presence of lymph nodes and
parathyroid tissue was also recorded in all cases. Gross examination
and sampling were performed in accordance with the College of
American Pathologists protocol for examination of thyroid specimens.22 Malignant cases were assessed using the College of
American Pathologists and American Joint Committee on Cancer
8th edition guidelines.11 Level sections and ancillary stains were
performed as needed for assessment. The findings, including
preoperative fine-needle aspiration cytology diagnosis, any molecular testing, and accompanying ultrasound findings, were reviewed
for the purpose of the study. Thyroid fine-needle aspiration
cytology results were rendered based on the Bethesda System for
Reporting Thyroid Cytopathology23 by using a standard template
that documents cytologic features at the time of pathology review.

RESULTS
Fifty thyroid resections via TOETVA were received in
pathology from 48 women and 2 men, ranging in age from
28 to 74 years (mean, 47 years) (Table 1). Forty-seven
patients had preoperative fine-needle aspiration cytology. In
the remaining 3 cases, a clinical diagnosis of ‘‘toxic
adenoma’’ or ‘‘nodule’’ was the indication for surgery.
Preoperative nodule sizes, taken from ultrasonographic
reports, ranged from 0.6 to 6.3 cm (mean, 2.6 cm). The
TOETVA resections included 41 thyroid lobectomies or
hemithyroidectomies, 7 total thyroidectomies, 1 isthmusectomy, and 1 cyst excision. The specimens weighed 2 to 44.9
g (mean, 16.3 6 13.4 g). The thyroid tissue was disrupted in
34 cases (68%) and intact in 16 (32%) (Figure 1, A through
2 Arch Pathol Lab Med

D). Twenty-three specimens (46%) showed fragmentation,
with a mean of 4 fragments (range, 2–8 fragments) per case.
Fragment sizes ranged from 0.1 to more than 4 cm. The
median nodule size in disrupted cases was 3 cm (range, 0.4–
6.3 cm; mean, 3.3 cm). The median nodule size in intact
cases was 1.9 cm (range, 0.8–5 cm; mean, 2.4 cm).
Microscopically, parathyroid tissue was found in 14 cases
(28%), ranging in size from 0.1 to 0.7 cm (mean, 0.4 cm).
Lymph nodes were identified in 10 cases (20%; average 2
nodes/case), all of which were peri-thyroidal (level VI).
Thirty-nine resection specimens were negative for carcinoma, comprising 35 cases of nodular hyperplasia, 2
Hürthle cell adenomas (HCAs), 1 follicular adenoma, and
1 noninvasive follicular thyroid neoplasm with papillary-like
nuclear features (NIFT-P). An additional HCA and NIFT-P
each were also diagnosed in 2 of the cases of PTC (described
further below). For all 4 follicular adenomas/HCAs and both
NIFT-Ps, microscopic examination of the tumor capsule was
possible, as it was largely intact. These tumors ranged in size
from 0.5 to 2.2 cm. The preoperative ultrasound sizes for
these lesions ranged from 1 to 2.8 cm. A total of 11 patients
had carcinoma at final diagnosis, all of which were PTC
(Figure 2, A through D). This included all 4 cases with a
preoperative diagnosis of suspicious or positive for PTC
(Bethesda V/VI), 2 FLUSs with nuclear atypia, and 1
follicular neoplasm (Bethesda III/IV); 4 carcinomas were
incidentally detected (Tables 2 and 3). There were 8
microcarcinomas, 2 follicular variant carcinomas, and 1
classic variant carcinoma. The mean PTC size was 0.8 cm
(range, 0.2–2.6 cm); this includes the size of 1 lesion that
was estimated (at least 2.6 cm) and excludes the size of 1
lesion that could not be determined on surgical pathology
(see below). One case showed metastatic disease to lymph
nodes (4 of 4 lymph nodes) with the size of the largest
lymph node measuring 0.6 cm with a 0.6-cm lymph node
tumor deposit and no extranodal extension. Six of these 11
thyroids (55%) were grossly disrupted, with a mean of 3
pieces (range, 2–4 pieces). In 2 cases—both with indeterminate cytology (Bethesda III) —tumor size, microscopic
ETE, and margin status could not be determined because of
specimen fragmentation. However, one of these tumors was
estimated to be at least 2.6 cm based on the surgical
pathology findings and had a preoperative ultrasound size
of 4.5 cm, and the other had a preoperative ultrasound size
of 3 cm. In each case, the tumor displayed follicular
architecture and the capsule could not be well visualized.
In one case, there were scattered papillae estimated to be
more than 1% of the lesion, and in the other case, areas of
solid and trabecular growth were present; these findings led
to diagnoses of carcinoma. In 2 cases of PTC, immunohistochemical stains were used as part of the diagnostic
workup. These stains included TTF1, thyroglobulin, calcitonin, estrogen receptor, b-catenin, and CD10. Additional
diagnoses that were noted, but not recorded in detail for the
purposes of this study, were chronic lymphocytic thyroiditis
and a background of nodular hyperplasia in cases where
tumors were present.
With respect to molecular analysis, 12 cases had molecular
testing performed on the preoperative fine-needle aspiration, including 8 cases of FLUS (Bethesda III), 2 cases
suspicious for PTC (Bethesda V) and 2 cases positive for PTC
(Bethesda VI). Methods included BRAF status by polymerase
chain reaction single-strand conformation polymorphism
analysis (10 cases) and next-generation sequence analysis
(ThyroSeq v2, Pittsburgh, Pennsylvania; 2 cases). BRAF
Clinicopathologic Characteristics of TOETVA—Smith et al

Table 1.

Summary of Clinicopathologic Findings (N ¼
50)
Characteristic

Age, mean (range), y
Sex, No.
Female
Male
Preoperative nodule size, mean (range), cm
FNA biopsy Bethesda classification
II
III/IV
V/VI
Extent of surgery
Lobectomy/hemithyroidectomy
Total thyroidectomy
Isthmusectomy
Cyst excision
Surgical pathology findingsa
Weight of specimen, mean (range), g
Fragmentation or disruption present, No. (%)
No. of tissue fragments, mean (range)
Parathyroid tissue present, No. (%)
Lymph nodes present, No. (%)
Nodular hyperplasia, No.
Benign/indolent tumor, No.
Tumor size, mean (range) cm
Carcinoma, No.
Incidentally detected
Preserved ability to evaluate all tumor
parametersb
Tumor size, mean (range), cmc
Indeterminate diagnosis, No.

Value
47 (28–74)
48
2
2.6 (0.6–6.3)
47
18
25
4
41
7
1
1
16.3 (2–44.9)
34 (68)
4 (2–8)
14 (28)
10 (20)
35
6
1.5 (0.5–2.2)
11
4
9
0.8 (0.2–2.6)
0

a

The total number of nodular hyperplasia, benign/indolent tumor, and
carcinoma diagnoses is 52, because of the presence of 2 benign/
indolent tumors diagnosed in cases that also showed carcinoma.
b
Tumor parameters include a definitive tumor size, margin status, and
microscopic extrathyroidal extension. In 2 cases, all 3 of these
parameters could not be accurately assessed.
c
This excludes 1 case of carcinoma where tumor size could not be
assessed upon pathologic examination and includes 1 case where
tumor was estimated to be at least 2.6 cm. Preoperative imaging for
these cases showed the lesions to be 4.5 and 3 cm.

V600E mutation was detected in 2 cases of PTC (both on
cytology and confirmed histologically); the remaining BRAF
mutation analyses were negative. ThyroSeq v2 detected an
NRAS (p.Q61R, c.182A.G) in 1 case of a Bethesda III lesion
that had a final diagnosis of follicular variant PTC (one of
the cases that was disrupted and unable to have tumor
parameters assessed). The other ThyroSeq v2 analysis was
negative and the final diagnosis was a nodular hyperplasia.
No molecular analyses were performed on resection
specimens.
The mean clinical follow-up time for all cases was 101
days (range, 4–460 days; SD ¼ 117 days). The mean clinical
follow-up time for malignant cases was 185 days (range, 30–
460 days). Four patients reported temporary postoperative
vocal cord paralysis that resolved within several weeks
following the surgery. In 1 case, vocal cord paralysis
remained for at least 1 year postoperation. Four patients
reported chin/neck numbness and/or paresthesias. No
instances of recurrent carcinoma were identified. Only one
Arch Pathol Lab Med

patient with PTC was offered postoperative radioactive
iodine because of metastatic disease involving 4 of 4 level VI
lymph nodes, as well as carcinoma extending to a single
cauterized edge in a disrupted specimen.
DISCUSSION
We presented detailed pathologic examination of 50
consecutive thyroid specimens resected using TOETVA
and its impact in the assessment of 17 tumors, including
11 PTCs, 4 adenomas, and 2 NIFT-Ps. We showed that
tissue disruption and/or fragmentation is frequent, seen in
approximately two-thirds of all cases. Although this did not
affect the final pathologic diagnosis in any of the 50 cases, in
2 cases of PTC, the tumor size, margin status, and
microscopic ETE could not be determined because of
fragmentation. These cases had indeterminate cytology
(Bethesda III) and accounted for the largest lesions on
preoperative ultrasound (3 and 4.5 cm) of the cases with a
neoplastic final diagnosis. Both cases showed predominantly follicular architecture. In both, invasion of the capsule
could not be assessed, but fortunately other histologic
findings led to a diagnosis of carcinoma. Given that invasion
into the surrounding thyroid parenchyma is critical in the
assessment of HCA versus Hürthle cell carcinoma, follicular
adenoma versus follicular thyroid carcinoma, and follicular
variant PTC versus NIFT-P, the inability to evaluate the
capsule in such cases may lead to ambiguity in distinguishing between benign and malignant entities. Cases classified
as HCA, follicular adenoma, or NIFT-P in this series showed
preoperative ultrasound sizes less than or equal to 2.8 cm.
Ten of the carcinomas in our series were classified as low
risk based on the American Thyroid Association risk
stratification.12 One case with lymph node metastasis was
classified as intermediate risk.
The clinical impact of reported pathologic findings in
TOETVA specimens may be significant, leading to overtreatment or undertreatment. Pathologists traditionally take
cautery effect on tumor as evidence of positive margin;
multiple cauterized fragments assessed in TOETVA specimens may lead to erroneous margin reporting. Undetermined margin status might lead to unnecessary radioactive
iodine therapy. Determining tumor size and focality can be
challenging when tumors are present in more than one
fragment. Adding the size of tumor in different fragments or
its determination by preoperative imaging may lead to
overestimation of pT stage and unnecessary therapy.13
Additionally, a false impression of microscopic ETE or
suspicion for ETE may be created through this fragmentation, further impacting management decisions.14 Per the
American Joint Committee on Cancer 8th edition guidelines,11 staging is based on gross ETE, which necessitates
correlation of macroscopic findings along with operative
and imaging findings. Fragmented or disrupted specimens
may pose a challenge in accurate evaluation of macroscopic
ETE.
Fragmentation may not be limited to the thyroid gland,
but indeed may involve lymph nodes or other structures of
the neck. The size and the location of involved lymph nodes
in the neck are factors informing further therapy, including
administration of radioactive iodine and/or external-beam
therapy (in some cases).11
The American Thyroid Association has not established
uniform indications and contraindications for TOETVA, but
has issued a general statement on remote-access thyroidecClinicopathologic Characteristics of TOETVA—Smith et al 3

Figure 1. Representative gross photographs of transoral vestibular-approach thyroidectomy specimens. A, Grossly intact lobectomy with an
indeterminate fine-needle aspiration (FNA) and a final diagnosis of noninvasive follicular neoplasm with papillary-like nuclear features (cut surface in
inset). B and C, Disrupted/fragmented specimens with a final diagnosis of goiter. D, A disrupted specimen that had an indeterminate FNA and a final
diagnosis of papillary thyroid carcinoma involving multiple fragments. Tumor parameters including margins and microscopic extrathyroidal extension
could not be determined.

tomy.15 Many tumors identified incidentally or even known
preoperatively—including the 11 in our study—are low-risk
tumors by morphology and size criteria.16 Fernandez-Ranvier
et al1 proposed several eligibility criteria, with favorable
features including the patient’s own motivation to avoid a
cervical scar, symptomatic benign nodules 6 cm or smaller,
cytologically indeterminate nodules (Bethesda III or IV
lesions) smaller than 6 cm, estimated thyroid diameter 10
cm or smaller on ultrasound, estimated gland volume 45 mL
or smaller on ultrasound, symptomatic Hashimoto thyroiditis, Graves disease (euthyroid, if possible), and differentiated
thyroid cancer smaller than 3 cm without ETE or lymph node
metastasis on preoperative ultrasonography. Unfavorable
features (substernal goiters, previous surgical intervention,
previous cervical radiotherapy) are provided with recommendation against TOETVA. Importantly, as FernandezRanvier et al1 noted, ‘‘more important than cosmetics is the
correct management of the patient’s thyroid pathology. . .guidelines set forth by the American Thyroid Association
should coincide with [these] recommendations. . .when
deciding to utilize the TOETVA.’’ With these eligibility criteria
in mind, preoperative cytopathologic diagnoses including
4 Arch Pathol Lab Med

indeterminate, suspicious, or malignant results are not
necessarily a contraindication for TOETVA.
Some authors have attempted to define indications for
TOETVA in the context of suspicious or malignant thyroid
nodules while avoiding any significant impact to critical
pathologic staging and prognostic parameters.14 One
selection criterion studied was the appropriate nodule
diameter that would obviate the need to disrupt the
specimen and protect the mental nerve from injury. Strict
preoperative size criteria would greatly decrease the
likelihood of specimen disruption, but would also narrow
the pool of patients who would be eligible for this surgery,
particularly those who have large malignant nodules and
still desire to avoid a cutaneous scar. Wu et al8 concluded
that the safest diameter to remove a suspicious or
malignant nodule is 20 mm. Razavi et al16 also outlined
certain indications and contraindications for TOETVA,
including a cutoff of 20 mm or smaller for malignant
cases. For nodules larger than 20 mm, other techniques
have been proposed to remove larger specimens without
injury to the mental nerve or fragmentation of the
specimen.9,17–19 Tai et al6 assessed 269 patients retrospecClinicopathologic Characteristics of TOETVA—Smith et al

Figure 2. Representative photomicrographs of neoplastic lesions in transoral endoscopic vestibular-approach thyroidectomy specimens.
Fragmented papillary thyroid carcinoma with tumor extending to a disrupted edge (A) and the classic nuclear features of papillary thyroid
carcinoma seen at higher power (B). Margin status, size, and microscopic extrathyroidal extension could not be assessed in this lesion and the
capsule could not be examined. Capsules in some lesions remained mostly intact, including a noninvasive follicular thyroid neoplasm with papillarylike nuclear features (C) and a Hürthle cell adenoma (hematoxylin-eosin, original magnifications 32 [A, C, and D] and 320 [B]).

tively who had a preoperative diagnosis of PTC via
cytopathology; most tumors identified were pT1a lesions
(,1 cm in size). Despite positive lymph nodes being
identified and 2 documented cases of ETE (pT3b disease as
defined by the American Joint Committee on Cancer 7th
edition,20 which included microscopic ETE), the authors of
this study do not comment on any challenges in
Table 2.

determining pathologic staging. The authors conclude that
TOETVA may be feasible for PTC larger than 1 cm.6
As noted above, some neoplasms in our series that
required complete examination of the lesion/capsule for
classification were amenable to diagnosis. These lesions
were 2.8 cm or less in greatest dimension. However, it is of
concern, from a surgical pathologist’s viewpoint, that an

Cytopathologic Classification Based on the Bethesda System for Reporting Thyroid Cytopathology of 47 Lesions
and Corresponding Final Surgical Pathology Diagnosisa
Final Histologic Diagnosis

Preoperative FNA Cytology Bethesda Categoryb

NH

FA

HCA

NIFT-P

PTC

II (n ¼ 18)
III/IV (n ¼ 25)
V/VI (n ¼ 4)

18
16
0

0
1
0

0
3
0

0
2
0

0
3
4

Abbreviations: FA, follicular adenoma; FNA, fine-needle aspiration; HCA, Hürthle cell adenoma; NH, nodular hyperplasia; NIFT-P, noninvasive
follicular thyroid neoplasm with papillary-like nuclear features; PTC, papillary thyroid carcinoma.
a
This table does not include lesions incidentally detected on final surgical pathology evaluation of the resection specimens (n ¼ 4).
b
Bethesda II: benign; Bethesda III: atypia/follicular lesion of undetermined significance; Bethesda IV: follicular neoplasm/suspicious for follicular
neoplasm; Bethesda V: suspicious for malignancy; Bethesda VI: malignant.
Arch Pathol Lab Med
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Table 3.

Details of Cases With Carcinoma Final Diagnosis

Case

Age,
y/Sex

Preoperative
Nodule
Size, cm

1

51/F

3.7

NFM

LL

2

42/F

2.2

HCN

RL

3

50/M

1.4

FLUS (BRAF mutation negative)

LL

4

56/F

1

SusPTC (BRAF mutation negative)

TT

5

68/F

2.4

HCN

RL

6

29/F

0.7

SusPTC

TT

7

46/F

3

RL

8

61/F

1.6

LL

9

48/F

0.6

FLUS (NRAS mutation positive;
p.Q61R, c. 182A .G)
PosPTC (positive for
BRAF V600E mutation)
PosPTC (positive for
BRAF V600E mutation)

imPTC (0.4)
Goiter
imPTC (0.7)
Goiter
imPTC (0.2)
NIFTP (1.4)
mPTC (0.4)
Goiter
imPTC (0.4)
HCA (1.6)
mPTC (0.8)
CLT
PTC-FVa,b

TT

10
11

70/F
51/F

1.3
4.5

FLUS (BRAF mutation negative)
FN

RL
RL

FNA Result

Procedure

Gross
Specimen
D or I

Specimen
Weight, g

I

9

D

14

I

10

I

14

D

8

I

19

D

10

PTC-CV (1.1)

I

8

mPTC (0.6); 4 lymph nodes
positive with largest tumor
deposit (0.6 cm)
mPTC (1)
PTC-FV (2.6)b,c

D

16

D
D

8.2
11.7

Final Pathologic
Diagnosis (Size, cm)

Abbreviations: CLT, chronic lymphocytic thyroiditis; D, disrupted; FLUS, follicular lesion of undetermined significance; FN, follicular neoplasm;
FNA, fine-needle aspiration; HCA, Hürthle cell adenoma; HCN, Hürthle cell neoplasm; I, intact; imPTC, incidental papillary thyroid
microcarcinoma; LL, left lobectomy; mPTC, papillary thyroid microcarcinoma; NFM, negative for malignant cells; NIFTP, noninvasive follicular
thyroid neoplasm with papillary-like nuclear features; PosPTC, positive for papillary thyroid carcinoma; PTC-CV, papillary thyroid carcinoma, classic
variant; PTC-FV, papillary thyroid carcinoma, follicular variant; RL, right lobectomy; SusPTC, suspicious for papillary thyroid carcinoma; TT, total
thyroidectomy.
a
The tumor size could not be measured on final pathology in this case because of specimen disruption.
b
Tumor parameters including microscopic extrathyroidal extension and margin status could not be assessed.
c
The tumor size was estimated to be at least 2.6 cm (could not be definitive because of disruption).

ambiguous diagnosis (eg, ‘‘follicular thyroid neoplasm,
cannot exclude malignancy’’) may need to be rendered on
lesions of this nature appearing in multiple fragments.
Moreover, given that subcentimeter PTC is often undetected
preoperatively (‘‘incidental’’), there exists an inherent risk in
every TOETVA procedure that fragmentation may lead to
diagnosis of an incidental malignancy that may not be
adequately pathologically assessed.
Of note, a preoperative pathologically confirmed diagnosis of poorly differentiated thyroid carcinoma and preoperative radiographic evidence of ETE have been regarded as
contraindications for TOETVA.21 We can find no mention in
the literature of whether adverse histology as diagnosed on
cytopathology (eg, hobnail variant, tall cell variant, or
dedifferentiation) has an impact on the indication for
TOETVA. Given the aggressive nature of these lesions, we
urge caution in considering these preoperative diagnoses—
if rendered—for TOETVA.
A limitation of this study is the sample size of 50 cases,
and we suspect that in larger series examining the
pathologic assessment of TOETVA specimens, instances of
fragmentation leading to diagnostic ambiguity between
benign and malignant entities is likely to occur. Additionally, the long-term follow-up on patients is limited. A final
limitation is that these 50 cases were among the first
performed in the United States, and may not represent
improvements in technique and refinement of indications
over time.
6 Arch Pathol Lab Med

To date, nearly 700 or more cases of TOETVA have been
reported,21 including 7 cases described previously by our
institution.10 Notably, these studies have not included
pathologists, and our series is the first to our knowledge
to report detailed pathologic findings in such cases. We
showed that TOETVA can be performed without compromising the pathologic assessment of neoplastic lesions in
the majority of cases (15 of 17). We also showed that in a
subset of cases tumor parameter evaluation is compromised
in the setting of PTC because of specimen fragmentation
and disruption. This appears to be the case as the lesions
increase in size (.3 cm), and this should be taken into
consideration when selecting patients for TOETVA with
indeterminate, suspicious, or malignant lesions on cytology.
Guideline development should also consider these potential
pathology limitations, and additional studies regarding the
pathology of these cases is needed to further inform such
guidelines.
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